Enhanced Stable Oral Suspensions of Baclofen

The present inventive concept provides improved oral suspensions of baclofen, overcoming the limitations of existing formulations by enhancing stability, shelf-life, and usability.

The original patent disclosed stable oral suspensions of baclofen, but the formulations may still be susceptible to degradation, oxidation, and viscosity issues. The present inventive concept addresses these limitations by introducing novel components and methods to improve the overall performance of baclofen suspensions.

The new claims introduce a system for stabilizing oral suspensions of baclofen by controlling the atmosphere, adding antioxidants, and using pH-adjusting agents. Additionally, the inventive concept includes methods for improving shelf-life, reducing viscosity, and preparing stable suspensions. These innovations enable the creation of more robust and user-friendly oral suspensions of baclofen.

The present inventive concept's novelty lies in the combination of controlled atmosphere storage, antioxidant addition, and pH-adjusting agents, which provide a synergistic effect in enhancing the stability and shelf-life of baclofen suspensions. The inventive step is the recognition of the need to address the limitations of existing formulations and the development of these novel solutions.

Alternative embodiments of the inventive concept could include the use of different antioxidants, pH-adjusting agents, or solubilizers. Variations could also involve different container materials, storage conditions, or mixing protocols to further optimize the performance of the oral suspensions.

The enhanced stable oral suspensions of baclofen have significant commercial potential in the pharmaceutical industry, particularly in the treatment of spasticity and other muscle-related disorders. The improved formulations could also expand into new markets, such as pediatric or geriatric care, where ease of use and stability are critical factors.